[go: up one dir, main page]

MX2013011767A - Composicion farmaceutica solida. - Google Patents

Composicion farmaceutica solida.

Info

Publication number
MX2013011767A
MX2013011767A MX2013011767A MX2013011767A MX2013011767A MX 2013011767 A MX2013011767 A MX 2013011767A MX 2013011767 A MX2013011767 A MX 2013011767A MX 2013011767 A MX2013011767 A MX 2013011767A MX 2013011767 A MX2013011767 A MX 2013011767A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
solid pharmaceutical
composition
redissolving
reconstitution
Prior art date
Application number
MX2013011767A
Other languages
English (en)
Inventor
Allen Ritter
Amy C Williams
Lars Waldmann
Huamin Zhang
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of MX2013011767A publication Critical patent/MX2013011767A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención descrita aquí pertenece a una composición farmacéutica sólida que comprende EC145 para la reconstitución, para proveer una solución para inyección intravenosa, particularmente a una composición farmacéutica sólida liofilizada que comprende EC145 que tiene una estabilidad adecuada para el almacenamiento a temperatura ambiental y que es capaz de redisolverse en un diluyente acuoso previo a la administración, así como a un proceso para su fabricación, a los productos farmacéuticos que comprenden la composición y a los métodos para el uso de la composición para el tratamiento del cáncer.
MX2013011767A 2011-04-12 2012-04-12 Composicion farmaceutica solida. MX2013011767A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161474428P 2011-04-12 2011-04-12
PCT/US2012/033312 WO2012142281A1 (en) 2011-04-12 2012-04-12 Solid pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2013011767A true MX2013011767A (es) 2013-11-01

Family

ID=47009691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011767A MX2013011767A (es) 2011-04-12 2012-04-12 Composicion farmaceutica solida.

Country Status (15)

Country Link
US (1) US20140030321A1 (es)
EP (1) EP2696684A4 (es)
JP (1) JP2014510791A (es)
KR (1) KR20140022879A (es)
CN (1) CN103607891A (es)
AU (1) AU2012242820A1 (es)
BR (1) BR112013026352A2 (es)
CA (1) CA2832858A1 (es)
CL (1) CL2013002938A1 (es)
EA (1) EA201391512A1 (es)
IL (1) IL228742A0 (es)
MX (1) MX2013011767A (es)
SG (1) SG194458A1 (es)
WO (1) WO2012142281A1 (es)
ZA (1) ZA201308414B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2945703A4 (en) 2013-01-15 2016-08-31 Teva Pharma ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF
US20140199286A1 (en) * 2013-01-15 2014-07-17 Teva Pharmaceutical Industries, Ltd. Lyophilization process

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030804A2 (en) * 1999-10-27 2001-05-03 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
WO2004069159A2 (en) * 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
FR2912406B1 (fr) * 2007-02-13 2009-05-08 Pierre Fabre Medicament Sa Sels cristalins anhydres de vinflunine, procede de preparation et utilisation en tant que medicament et moyen de purification de la vinflunine.
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
EP2445506B1 (en) * 2009-06-24 2014-12-31 Entarco SA The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
AU2010278734A1 (en) * 2009-07-31 2012-02-23 Endocyte, Inc. Folate-targeted diagnostics and treatment
MX2013005196A (es) * 2010-11-12 2013-06-28 Endocyte Inc Metodos para tratamiento del cancer.

Also Published As

Publication number Publication date
JP2014510791A (ja) 2014-05-01
SG194458A1 (en) 2013-12-30
CL2013002938A1 (es) 2014-08-22
US20140030321A1 (en) 2014-01-30
IL228742A0 (en) 2013-12-31
EA201391512A1 (ru) 2014-05-30
CN103607891A (zh) 2014-02-26
WO2012142281A1 (en) 2012-10-18
KR20140022879A (ko) 2014-02-25
CA2832858A1 (en) 2012-10-18
BR112013026352A2 (pt) 2016-07-26
ZA201308414B (en) 2015-05-27
EP2696684A4 (en) 2014-11-05
EP2696684A1 (en) 2014-02-19
AU2012242820A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
ZA202303593B (en) Liquid protein formulations containing viscosity-lowering agents
IN2015KN00005A (es)
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
IN2012DE00337A (es)
PE20140616A1 (es) Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri)
EP4385517A3 (en) Degarelix drug product
MX2015012078A (es) Composicion que contiene enzimas digestivas y nutrientes adecuados para la administracion enteral.
IN2013MU00711A (es)
MX2021002633A (es) Dispersiones solidas de bendamustina e infusion continua.
HK1217633A1 (zh) 冻乾方法
MY191043A (en) Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof
SG194458A1 (en) Solid pharmaceutical composition
GB201122430D0 (en) Reconstitution method for high concentration dry protein formulation
PH12017501005A1 (en) Injectable formulations of paracetamol
RU2011153314A (ru) Способ введения лекарственных средств в полость коленного сустава у собак
UA80396U (ru) Способ лечения острых асептических синовитов у лошадей
UA69675U (ru) Способ лечения стеатоза печени у больных туберкулезом легких
GR1008227B (el) Σταθερο φαρμακευτικο σκευασμα ενος βενζιμιδαζολικου αναστολεα της αντλιας πρωτονιων και μεθοδος για την παρασκευη αυτου
HK1226310A1 (en) Liquid protein formulations containing water soluble organic dyes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal